Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

NCT07198633 is registered in ClinicalTrials.gov with Qilu Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07198633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07198633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
Lead sponsor
Qilu Pharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 5, 2025
Completion date
December 31, 2027
Enrollment
212 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced prostate cancer